Authors
Latest:
Dr. Maris on Key Results From the OUTREACH Trial of Liso-cel in DLBCLMichael Maris, MD, discusses key efficacy and safety data from the phase 2 OUTREACH trial in diffuse large B-cell lymphoma.
Latest:
Dr. Osipov on the Role of Combination Immunotherapy Across Multiple Tumor TypesArsen Osipov, MD, discusses the role of combination immunotherapy across multiple tumor types.
Latest:
Treatment Advances in HR+ Breast CancerA panel of experts who treat breast cancer close out a discussion on the use of newer therapies, including CDK4/6 inhibitors, based on outcomes demonstrated by recent clinical trials.
Latest:
Dr. Cavnar on the Use of Hepatic Artery Infusion Pumps in CRC With Liver MetastasesMichael J. Cavnar, MD, discusses the use of hepatic artery infusion pumps in patients with colorectal cancer with liver metastases.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Career Options for Graduating Oncology Fellows at the NIH and FDAPeter J. DeMaria, MD and Jennifer J. Gao, MD shed light on how graduating fellows seeking a rewarding and intellectually challenging career on the frontier of cancer drug development could be well served to consider a position of federal service at the NIH or FDA.
Latest:
Dr Ademuyiwa on the Sequencing of First-line CDK4/6 Inhibitors in HR+/HER2– Breast CancerFoluso Bisi Ademuyiwa, MD, MPH, MSCI, discusses the optimal sequencing of current CDK4/6 inhibitors in the first-line setting for hormone receptor (HR)–positive, HER2-negative breast cancer based on updated efficacy and safety data.
Latest:
Exploring Emerging Data in DLBCLA panel of experts in lymphoma reflect on major data that came out of the ASCO 2021 Virtual Meeting.
Latest:
Rapid Readouts: Final Analysis Results From the Phase 3 TITAN StudyKim N. Chi, MD, presents slides from the 2021 ASCO Genitourinary Cancers Symposium for the final results from the phase 3 TITAN study of apalutamide versus placebo in patients with metastatic castration-sensitive prostate cancer receiving androgen deprivation therapy.
Latest:
Ongoing Research Could Help Define the Role of Immunotherapy in Earlier-Stage HCCJames J. Harding, MD, discusses how immunotherapy could play a role in earlier stages in hepatocellular carcinoma.
Latest:
Dr. de Ligt on Using Symptom Burden to Tailor Follow-Up Care in Breast Cancer SurvivorsKelly de Ligt, PhD, discusses subgroups of symptom burden seen in breast cancer survivors.
Latest:
Dr. Rocconi on the Impact of the SORAYA Trial in FRα+ Ovarian Cancer TreatmentRodney Rocconi, MD, discusses the impact of the phase 3 SORAYA trial in folate receptor alpha–positive ovarian cancer.
Latest:
Dr. Oliveira on the Examination of Camizestrant Vs Fulvestrant in ER+/HER2- Breast CancerMafalda Oliveira, MD, PhD, discusses the examination of camizestrant vs fulvestrant in estrogen receptor-positive, HER2-negative advanced breast cancer.
Latest:
Dr Mitzman on the Use of Adjuvant Atezolizumab After Chemotherapy in Resectable NSCLCBrian Mitzman, MD, FACS, FCCP, discusses the use of adjuvant atezolizumab following platinum-based chemotherapy in patients with resectable non–small cell lung cancer.
Latest:
Trastuzumab Deruxtecan in the Neoadjuvant SettingClosing thoughts on the TALENT study concerning the use of neoadjuvant trastuzumab deruxtecan in patients with HER2-low, HR+ early-stage breast cancer.
Latest:
Dr. Mian on the Investigation into the Synchronous Up-front Setting of Metastatic Prostate CancerOmar Mian, MD, PhD, discusses the ongoing investigation into the synchronous up-front setting of metastatic prostate cancer.
Latest:
Dr Porter on Community-Based CAR T-Cell Therapy Administration for R/R CLLDavid L. Porter, MD, discusses the utility of CAR T-cell therapy in the community setting for relapsed/refractory chronic lymphocytic leukemia.
Latest:
Dr Dorritie on the Clinical Implications of the 5-Year Follow-Up Data From CAPTIVATE in CLL/SLLKathleen A. Dorritie, MD, discusses 5-year of follow-up data from the CAPTIVATE trial in chronic lymphocytic leukemia and/or small lymphocytic lymphoma.
Latest:
ESMO 2021 Updates in Gastric Cancer and Colorectal CancerSam Klempner, MD; Daniel H. Ahn, DO; Nataliya V. Uboha, MD, PhD; and Manish A. Shah, MD, FASCO, review recent updates in second-line gastric cancer, CAR T-cell therapy in solid tumors, and colorectal cancer presented at ESMO 2021.
Latest:
Kay Macleod Named Associate Director for Basic Sciences for the Cancer CenterKay Macleod, PhD, has been appointed as the associate director for Basic Sciences for the University of Chicago Medicine Comprehensive Cancer Center.
Latest:
Dr. Garg on the Need for Novel Imaging Techniques in nmCRPCNatasha Garg, DO, discusses the utility of novel imaging techniques in patients with nonmetastatic castration-resistant prostate cancer.
Latest:
Henry Ford Health + MSU Health Sciences Funds Five Cancer Research Grants to Advance Cancer Medicine, Combat Health DisparitiesHenry Ford Health + Michigan State University Health Sciences announced its funding of 5 cancer research grants of up to $100,000 each. These 5 grants follow an initial wave of funding from the partnership, in which 18 pilot grants of up to $25,000 each were funded in May 2022.
Latest:
Dr. Strickler on the Results of Tucatinib Monotherapy in HER2+ CRCJohn H. Strickler, MD, discusses the results of tucatinib monotherapy in HER2-positive colorectal cancer.
Latest:
Overall Survival After Surgery for Spinal Metastases Has Improved Over the Past Two DecadesPostoperative survival after surgery for spinal metastases has improved over the past 20 years, particularly in patients with kidney, breast, lung, and colon tumors metastatic to the spine.
Latest:
Gymnastics Makes Me a Better OncologistValentina Baez Sosa, MD, shares how her early life experiences in gymnastics and coaching have helped her become a better hematology/oncology physician.
Latest:
Dr. Garber on the Efficacy of Adjuvant Olaparib in High-Risk, HER2-Negative Breast CancerJudy Garber, MD, MPH, discusses the efficacy of adjuvant olaparib in patients with high-risk, HER2-negative breast cancer, as demonstrated in the phase 3 OlympiA trial.
Latest:
Dr. Kindsfather on the Evolution of Reflex Testing in Lung CancerScott K. Kindsfather, MD, discusses the evolution of reflex testing in lung cancer.
